Clinical Trial Results:
A randomised controlled trial to compare the effect of micronized progesterone and Medroxyprogesterone Acetate on the vascular elasticity, lipid profile and coagulation cascade of women with premature ovarian failure.
Summary
|
|
EudraCT number |
2012-004511-30 |
Trial protocol |
GB |
Global end of trial date |
23 Sep 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jul 2019
|
First version publication date |
29 Jul 2019
|
Other versions |
|
Summary report(s) |
FINAL STUDY REPORT |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
POF01
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
King's College Hospital NHS Foundation Trust
|
||
Sponsor organisation address |
Denmark Hill, London, United Kingdom, SE5 9RS
|
||
Public contact |
Haitham Hamoda, King's College Hospital NHS Foundation Trust, 0044 02032995390, haitham.hamoda@nhs.net
|
||
Scientific contact |
Haitham Hamoda, King's College Hospital NHS Foundation Trust, 0044 02032995390, haitham.hamoda@nhs.net
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 Sep 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
23 Sep 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Sep 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Primary Objective:
To assess the effect of micronized progesterone and medroxy progesterone acetate on vascular elasticity. This will be assessed by examining the changes in pulse wave analysis in women with premature ovarian failure receiving combined oestrogen/progestogen HRT.
|
||
Protection of trial subjects |
Prior to randomisation, the participants will be asked to stop their current treatment regimen for a total of 1 month, to ensure an adequate washout time period has been accounted for. This washout time frame has been based on other published trials. It accounts for the half life of the medication. It is necessary to ensure that previous treatments do not influence or impact on the trial results. There is no evidence to suggest any risk from stopping their current treatment regime for this short duration.
|
||
Background therapy |
Combined HRT is the recommended treatment in women with POI until the natural age of the menopause. There are many different varieties. This study assessed two different progesterone preparations given in combination with transdermal oestrogen. If the subjects were previously prescribed HRT, then a wash out period of 4-6 weeks was advised prior to starting the new preparation. Each treatment arm was prescribed a type of HRT as treatment is recommended. No patient was given a placebo. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Jan 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 68
|
||
Worldwide total number of subjects |
68
|
||
EEA total number of subjects |
68
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
68
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Participants were recruited from King’s College London NHS Foundation Trust over a 30 month period between 2013 and 2016. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Prior to randomisation, the participants will be asked to stop their current treatment regimen for a total of 1 month, to ensure an adequate washout time period has been accounted for. There is no evidence to suggest any risk from stopping their current treatment regime for this short duration. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall Trial (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Blinding implementation details |
Open label trial
|
||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Group A - Utrogestan | ||||||||||||||||||||||||
Arm description |
Utrogestan, oral, 200 mg/24 hours from days 15-26 of a 28 days cycle. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Utrogestan
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Utrogestan, oral, 200 mg/24 hours from days 15-26 of a 28 days cycle.
|
||||||||||||||||||||||||
Arm title
|
Group B - Provera | ||||||||||||||||||||||||
Arm description |
Medroxyprogesterone Acetate, Provera, oral, 10 mg/24 hours from days 16-26/cycle. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Provera
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Medroxyprogesterone Acetate, Provera, oral, 10 mg/24 hours from days 16-26/cycle.
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
Overall Trial
|
|||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group A - Utrogestan
|
||
Reporting group description |
Utrogestan, oral, 200 mg/24 hours from days 15-26 of a 28 days cycle. | ||
Reporting group title |
Group B - Provera
|
||
Reporting group description |
Medroxyprogesterone Acetate, Provera, oral, 10 mg/24 hours from days 16-26/cycle. |
|
||||||||||
End point title |
The mean changes in the vascular elasticity. [1] | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Changes in vascular elasticity between baseline and visit 5
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: There was no statistical difference seen between the 2 treatment arms for the primary endpoint. Please see attached report for other endpoint analysis. |
||||||||||
|
||||||||||
Attachments |
FINAL STUDY REPORT |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From first dose of IMP until 30 days post last dose of IMP.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group A - Utrogestan
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group B - Provera
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: As this was a low risk trial accepted through the notification scheme as being as no greater risk than standard of care, no AEs were recorded. Only symptoms were recorded patient completed questionnaires. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/24072634 |